Retatrutide isn't expected to launch in the UK until at least mid-2026
In a statement made earlier this year, Dave Moore, executive vice president of US Operations at Novo Nordisk said: As the FDA has warned, compounders cannot rely on mere pretextual differences between unapproved compounded drugs and FDA-approved medicines under the guise of making personalized drugs in order to evade federal law. Likewise, Lilly intends to monitor the situation: There is no generic version of Mounjaro or Zepbound, Lillys FDA-approved tirzepatide medicines, and mass compounding of tirzepatide is unlawful, says the Lilly spokesperson
How to Get There You can reach this colorful district in various ways, depending on your starting point
Saxenda (liraglutide) is a daily injection made by the same manufacturer as Wegovy, Novo Nordisk
Whilst these results are notable, direct comparisons with currently approved agents should be interpreted with caution: such comparisons are indirect, based on different trial designs, populations, durations, and background interventions (including lifestyle counselling provided alongside study drug), and cannot be treated as equivalent to head-to-head evidence
